Original document(8 pages) Authorized document(7 pages) 中文版
    The health-care product with the function of regualting blood lipid is made up by using active component formed from crataegus fruit extract, lycium berry extract, alisma tuber extract and soyabean extract according to the weight ratio of 60-180:40-120:25-75:10-30. It is reliable in therapeutic effect and is safe.
Application Number
申请号
01113266 Application Date
申请日
2001.07.05
Title 名称 Health-care product capable of regulating blood-lipid and its preparation method
Publication Number
公开号
1394614 Publication Date
公开日
2003.02.05
Approval Pub. Date Granted Pub. Date 2005.08.31
International Classification 分类号 A61K35/78,A61P3/06
Applicant(s) Name
申请人
Shenzhen Taitai Pharmaceutical Industry Co. Ltd.
Address 地址 518008
Inventor(s) Name 发明人 Feng Kaidong, Wang Zhian
Attorney & Agent 代理人 sun tigong
More information 更  多  信  息


 Related patents information
Chinese medicine preparation for treating climacteric metancholia of women
Health-care product for improving sleep and increasing bone density
Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying
Sobering-up liver-protecting medicine composition for preventing chemical liver damage and its prepn process
Externally applied medicinal composition for resisting inflammation and repressing and killing bacteria and preparing method
Anti inflammatory bacteria inhibiting medicinal composition and its preparation method
Composition for improving memory and preparation thereof
crystallized (+)-(1S,2S,3S,4R,5R)-1-amido-5-hydroxymethyl-N-2(1,3-dihydroxypropyl)-2,3,4-cyclohexanetriol and its preparation method
(+)-(1S,2S,3S,4R,5R)-1-amido-5-hydorxymethyl-N-2-(1,3-dihydroxypropyl)-2,3,4-cyclohexanetriol preparation method
Application of a kind of alpha glycosidase inhibitor in preparation of medicine to prevent or treat diabetic microvascular complication
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.